Stay updated with breaking news from Marimar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Larimar Therapeutics, Inc. announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich s. | May 16, 2023 ....
BALA CYNWYD, Pa. — BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. on Monday reported a loss of $6.5 million in its first quarter. On a per-share basis, the Bala Cynwyd,. | May 15, 2023 ....
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich s Ataxia and First Quarter 2023. | May 15, 2023 ....
SAN DIEGO (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.15 A.M. ET).In the Green Neptune Wellness Solutions Inc. (NEPT) is up over 61% ....